RT Journal Article
SR Electronic
T1 Computational modelling of EEG and fMRI paradigms reveals a consistent loss of pyramidal cell synaptic gain in schizophrenia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.07.21249389
DO 10.1101/2021.01.07.21249389
A1 Rick A Adams
A1 Dimitris Pinotsis
A1 Konstantinos Tsirlis
A1 Leonhardt Unruh
A1 Aashna Mahajan
A1 Ana Montero Horas
A1 Laura Convertino
A1 Ann Summerfelt
A1 Hemalatha Sampath
A1 Xiaoming Michael Du
A1 Peter Kochunov
A1 Jie Lisa Ji
A1 Grega Repovs
A1 John D Murray
A1 Karl J Friston
A1 L Elliot Hong
A1 Alan Anticevic
YR 2021
UL http://medrxiv.org/content/early/2021/01/08/2021.01.07.21249389.abstract
AB Diminished synaptic gain – the sensitivity of postsynaptic responses to neural inputs – may be a fundamental synaptic pathology in schizophrenia. Evidence for this is indirect, however. Furthermore, it is unclear whether pyramidal cells or interneurons (or both) are affected, or how these deficits relate to symptoms. Participants with schizophrenia (Scz, n=108), their relatives (n=57), and controls (n=107) underwent three electroencephalography paradigms – resting, mismatch negativity, and 40 Hz auditory steady-state response – and resting functional magnetic resonance imaging. Dynamic causal modelling was used to quantify synaptic connectivity in cortical microcircuits. Across all four paradigms, characteristic Scz data features were best explained by models with greater self-inhibition (decreased synaptic gain), in pyramidal cells. Furthermore, disinhibition in auditory areas predicted abnormal auditory perception (and positive symptoms) in Scz, in three paradigms. Thus, psychotic symptoms of Scz may result from a downregulation of inhibitory interneurons that may compensate for diminished postsynaptic gain in pyramidal cells.Competing Interest StatementRAA, DP, KT, LU, AM, AMH, LC, AS, XMD, HS, PK, GR and KJF have no competing interests to declare. JLJ, JDM and AA consult for RBNC (formerly BlackThorn Therapeutics) and are listed as co-inventors on the following pending patent: Anticevic A, Murray JD, Ji JL: Systems and Methods for Neuro-Behavioral Relationships in Dimensional Geometric Embedding (N-BRIDGE), PCT International Application No. PCT/US2119/022110, filed March 13, 2019. JDM holds stock in BlackThorn Therapeutics. LEH has received or plans to receive research funding or consulting fees on research projects from Mitsubishi, Your Energy Systems LLC, Neuralstem, Taisho, Heptares, Pfizer, Luye Pharma, Sound Pharma, Takeda, and Regeneron. AA is also a SAB member for BlackThorn Therapeutics.Funding StatementRAA is an MRC Skills Development Fellow (MR/S007806/1) and has been supported by a UCL Bogue Research Fellowship, the Academy of Medical Sciences (AMS-SGCL13-Adams), the National Institute of Health Research (CL-2013-18-003), and the NIHR UCLH Biomedical Research Centre. JDM is funded by NIH grant MH112746. KJF is funded by the Wellcome Trust (Ref: 088130/Z/09/Z).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data were collected from studies sponsored by the National Institute of Health (MH085646 and DA027680) and under human subject protocols approved by the University of Maryland, Baltimore, Institutional Review Board (HP-00045716 and HP-00043082) and University College London Research Ethics Committee (4356/003).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request to Prof Elliot Hong.